BioVie Inc

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

CARSON CITY, Nev., Aug. 31, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced it will host a virtual KOL event titled NE3107―Putting Data in Context, ahead of the upcoming Phase 3 results in Alzheimer's Disease. The event will take place on Thursday, September 7, 2023 at 2:30pm ET. To register, click here.

BioVie to Host Virtual KOL Event on NE3107 in Alzheimer's Disease on September 7, 2023

The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -26.93% in 4 Weeks, Here's Why BioVie Inc. (BIVI) Looks Ripe for a Turnaround

BioVie Inc. (BIVI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI)

BioVie Inc (NASDAQ:BIVI) said new preclinical data characterizing its lead drug candidate NE3107's mechanism in action is being presented at the 2023 International Congress of Parkinson's Disease and Movement Disorders (MDS) being held in Copenhagen, Denmark from August 27 to 31. BioVie CEO Cuong Do said that the results and analysis presented at the MDS this week added to the growing body of data for NE3107 that supports the company's core understanding of this molecule and its potential in diseases such as Parkinson's Disease (PD).

BioVie showcases promising data for NE3107 at international Parkinson's Disease event

CARSON CITY, Nev., Aug. 28, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced details of three presentations given from studies of NE3107 in the treatment of Parkinson's Disease (PD) at the 2023 International Congress of Parkinson's Disease and Movement Disorders (MDS), being held in Copenhagen, Denmark August 27-31, 2023.

BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson's Disease and Movement Disorders

Down -23.45% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI)

Soligenix

ORLANDO, FL / ACCESSWIRE / August 11, 2023 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Soligenix, Inc. (Nasdaq:SNGX) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, August 12, at 7 p.m. Eastern Time (ET).

BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

BioVie Inc (NASDAQ:BIVI) has issued a letter to shareholders providing an update on its progress and recent findings. The letter highlights the company's excitement and optimism regarding the Phase 3 trial for NE3107 in Alzheimer's Disease (AD), which is expected to release its results later this year.

BioVie updates on its progress and recent findings

CARSON CITY, Nev., July 18, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today issued the following letter to shareholders:

BioVie Issues Letter to Shareholders

BioVie Inc (NASDAQ:BIVI) presented a poster over the weekend showcasing the epigenetic basis for how its drug candidate NE3107 may have regulated specific genes in a way that delivers cognitive improvements for patients with clinical dementia.  The poster was presented Sunday at the Alzheimer's Associate's International Conference (AAIC) in Amsterdam, which is being held July 16-20.

BioVie's clinical dementia drug NE3107 shown to reduce DNA methylation

CARSON CITY, Nev., July 17, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data from a poster detailing the epigenetic basis for how in a Phase 2 exploratory biomarker study its drug candidate NE3107 may have potentially regulated specific genes in a manner significantly correlated with observed cognitive and biomarker improvements. The poster was presented yesterday at the Alzheimer's Associate's International Conference (AAIC) held in Amsterdam July 16-20, 2023.

BioVie Presents Data Showing How NE3107 May Potentially Regulate DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

BioVie Inc (NASDAQ:BIVI) announced that a poster detailing how its drug candidate NE3107 regulated specific genes in a way significantly correlated with observed cognitive and biomarker improvements will be presented at the Alzheimer's Associate's International Conference being held in Amsterdam this weekend from July 16 to 20. The company said the new data being presented shows how NE3107 could potentially change or affect the degree of methylation of specific genes correlated with various disease markers.

BioVie to present promising new data for drug candidate NE3107 at Alzheimer's conference

CARSON CITY, Nev., July 10, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster detailing the genetic basis for how its drug candidate NE3107 regulated specific genes in a manner significantly correlated with observed cognitive and biomarker improvements will be presented this weekend at the Alzheimer's Associate's International Conference (AAIC) to be held in Amsterdam July 16-20, 2023.

BioVie to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

BioVie Inc (NASDAQ:BIVI) announced that baseline data from a multicenter, randomized, placebo-controlled Phase 3 study of its Alzheimer's Disease treatment was presented at the 83rd Scientific Sessions of the American Diabetes Association over the weekend in San Diego.  The company's treatment, NE3107, is an oral small molecule, blood-brain permeable anti-inflammatory insulin sensitizer that binds extracellular signal-regulated kinase.

BioVie presents Phase 3 study of Alzheimer's treatment at San Diego medical conference

Baseline Data from Phase 3 Trial of NE3107 Presented as Poster at the American Diabetes Association Annual Meeting Baseline Data from Phase 3 Trial of NE3107 Presented as Poster at the American Diabetes Association Annual Meeting

BioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer's Disease

BioVie will produce some lateral data from its phase 3 trial tomorrow. I was not overly impressed by its Alzheimer's program; the ascites program seemed more promising. The company is precariously low on cash. I will avoid for the time being.

BioVie: Not Investible For Its Alzheimer's Program

BioVie Inc (NASDAQ:BIVI) has announced that it will be added as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the US market opens on June 26, as part of the 2023 Russell indexes reconstitution.  The company noted that membership in the Russell 2000 Index, which remains in place for one year, is based on membership in the broad-market Russell 3000 Index.

BioVie set to join Russell 2000 and Russell 3000 indexes

CARSON CITY, Nev., June 23, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that the Company will be added as a member of the US small-cap Russell 2000® and Russell 3000® Indexes, effective after the US market opens on June 26, as part of the 2023 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. The stock also was automatically added to the appropriate growth and value indexes.

BioVie Set to Join the Russell 2000® and Russell 3000® Indexes

BioVie Inc (NASDAQ:BIVI) said it will present an abstract showcasing baseline data from its Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer's disease at the 83rd Scientific Sessions of the American Diabetes Association. The event is scheduled for June 23-26 in San Diego, the company said.

BioVie to present Phase 3 study data at American Diabetes Association conference

CARSON CITY, Nev., June 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract highlighting baseline data from its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer's disease will be presented as a poster at the 83rd Scientific Sessions of the American Diabetes Association, to be held June 23-26, 2023 in San Diego, CA.

BioVie To Present of NE3017 in Alzheimer's Disease Data at 83rd Scientific Sessions of the American Diabetes Association

BioVie Inc (NASDAQ:BIVI) has announced that a poster detailing the supporting data and rationale for a potentially pivotal clinical trial of NE3107 in the treatment of Parkison's Disease was presented at the 2023 World Congress on Parkison's Disease and Related Disorders (IAPRD), which held in Chicago on May 13-16, 2023. The drug therapies developer said highlights from the NE3107 study included patients treated with NE3107 + carbidopa/levodopa (C/L) experiencing greater improvements in their Motor Disease Society- Unified Parkinson's Disease Rating Scale (MDS UPDRS) Part III score than patients treated with placebo + C/L at the 2- and 3-hour marks.

BioVie presents rationale for NE3107 trial in Parkinson's Disease treatment at IAPRD in Chicago

CARSON CITY, Nev., May 16, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster detailing the supporting data and rationale for a potentially pivotal clinical trial of NE3107 in the treatment of Parkison's Disease was presented at the 2023 World Congress on Parkison's Disease and Related Disorders (IAPRD), held in Chicago, IL May 13-16, 2023.

BioVie Presents Rationale for Potentially Pivotal Trial of NE3107 in the Treatment of Parkinson's Disease at 2023 International Association of Parkinsonism and Related Disorders World Congress

By targeting inflammation as a novel pathway, clinical-stage biotechnology company BioVie Inc (NASDAQ:BIVI) aims to discover treatments for neurological and neurodegenerative disorders and advanced liver disease.  As BioVie CEO Cuong Do told Proactive, the company's purpose is to create new solutions that enable people to live healthier lives as they age.

BioVie aims to treat Parkinson's and Alzheimer's by focusing on inflammation

BioVie Inc (NASDAQ:BIVI) announced Thursday that a data abstract from its Phase 2 open-label trial of its degenerative dementia drug candidate has been accepted for presentation at the 78th Annual Scientific Convention of the Society of Biological Psychiatry. The event will be held April 27-29 in San Diego, with BioVie's presentation slated for April 28 at 5 pm PT.

BioVie's degenerative dementia drug candidate to be presented at psychiatry conference

CARSON CITY, Nev., April 20, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a data abstract from its Phase 2 open label trial evaluating NE7107 in degenerative dementias has been accepted for presentation at the 78th Annual Scientific Convention of the Society of Biological Psychiatry , to be held in San Diego, CA April 27-29, 2023.

News for BioVie Inc Stock (BIVI)